These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 25882231)

  • 1. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Spanos K; Giannoukas AD
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
    Hurst KV; Lee R; Milosevic I; Handa A
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
    [No Abstract]   [Full Text] [Related]  

  • 5. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants in the management of venous thromboembolism: a major advance?
    Sciascia S; Hunt BJ
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
    [No Abstract]   [Full Text] [Related]  

  • 7. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
    Dobesh PP; Fanikos J
    Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New oral anticoagulants for acute venous thromboembolism.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):3-4. PubMed ID: 24419296
    [No Abstract]   [Full Text] [Related]  

  • 14. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
    Yeh CH; Gross PL; Weitz JI
    Blood; 2014 Aug; 124(7):1020-8. PubMed ID: 24923298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-specific oral anticoagulants: practice issues for the clinician.
    Plitt A; Giugliano RP
    Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New anticoagulants for the prevention of thromboembolism.
    Lepic K; Crowther M
    Curr Pharm Des; 2010; 16(31):3472-4. PubMed ID: 20858184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ["Xa-tra-xa": opportunities and open questions about new anticoagulants].
    Beer JH
    Praxis (Bern 1994); 2011 Aug; 100(16):947. PubMed ID: 21910293
    [No Abstract]   [Full Text] [Related]  

  • 20. New oral therapies for the prevention and treatment of venous thromboembolism.
    Hellwig T; Gulseth M
    Am J Health Syst Pharm; 2013 Jan; 70(2):113-25. PubMed ID: 23292264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.